Targeted IVD antibodies Cell Marque, now part of MilliporeSigma, specializes in primary antibodies for in vitro diagnostics, presenting a clear opportunity to upsell core antibody capabilities and IVD-ready reagents to labs focusing on diagnostic accuracy and reproducibility.

Expanded microscopy line The new microscopy product line across Histology, Hematology, Cytology, and Bacteriology suggests bundled lab solutions; sales outreach can bundle primary antibodies with the expanded microscopy portfolio to drive higher per-site adoption in pathology and research labs.

Recent product launches Uroplakin II and H3 K27M introductions indicate active portfolio growth in cancer and neuro-oncology markers; leverage these launches to target institutions building diagnostic panels for urothelial cancers and diffuse midline gliomas.

Mid-size growth potential With revenue in the 25–50 million range and a leaner employee base, Cell Marque/MilliporeSigma can be positioned as a cost-effective, high-value partner for mid-sized labs seeking reliable antibodies and validated IHC reagents at scale.

Competitive positioning As part of Merck KGaA’s life science portfolio, there is a credibility and supply-chain advantage; sales teams can emphasize global support, quality assurance, and cross-sell opportunities with complementary MilliporeSigma products to existing customers of diagnostic labs and contract service providers.